Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- PANW +7.7%, NTNX +6.8%, LULU +5%, AVIR +4.3%,
M&A news:
- CAAS +1.5% (receives revised going-private proposal for $5.45/share)
- ACOR +1% (adopts poison pill 'in response to the recent accumulations of significant portions of Acorda's outstanding Common Stock'), .
Other news:
- APVO +82.7% (Aptevo Therapeutics and MorphoSys end joint development and commercialization agreement for MOR209/ES414; Aptevo regains worldwide rights - preliminary phase I data show markedly lower anti-drug antibody titers; Aptevo Therapeutics also signs agreement for up to $74.5 million to sell hyperimmune commercial products; provides significant non-dilutive funding to execute R&D Strategy)
- IOVA +11.3% ( FDA has granted Fast Track designation for LN-144, the Company's adoptive cell therapy using its TIL technology, for the treatment of advanced melanoma)
- DRYS +2.9% (commencement of its previously announced rights offering )
- THC +2.8% (commences Board refreshment process, implements shareholder rights plan to protect NOLs)
- BGNE +1.6% (BeiGene to close strategic oncology collaboration with Celgene Corporation)
- NKE +1.3% (following LULU results)
- ETP +1.1% (announces FERC approval to put Phase 1A of the Rover Pipeline in service; natural gas service to begin from Cadiz to Defiance August 31)
Analyst comments:
- N/A